Patients with advanced RET-rearranged NSCLC have shown clinical responses to treatment with multi-targeted inhibitors such as cabozantinib and vandetanib (drugs approved for use in advanced thyroid medullary carcinoma) in several early studies; the safety profile of these drugs also appears manageable [23, 24]. The gene discussed is RET; the disease is non-small cell lung carcinoma.